Re-inventing a better wheel? Serplulimab for squamous cell lung cancer

Immune checkpoint inhibitors have reshaped the treatment landscape of non-small cell lung cancer (NSCLC). However, chemoimmunotherapy trials dedicated to squamous NSCLC are limited. In this issue of Cancer Cell, Zhou et al. demonstrate serplulimab plus chemotherapy as an effective first-line regimen to treat patients with advanced squamous NSCLC. Immune checkpoint inhibitors have reshaped the treatment landscape of non-small cell lung cancer (NSCLC). However, chemoimmunotherapy trials dedicated to squamous NSCLC are limited. In this issue of Cancer Cell, Zhou et al. demonstrate serplulimab plus chemotherapy as an effective first-line regimen to treat patients with advanced squamous NSCLC. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Zhou et al.Cancer CellJanuary 4, 2024In BriefZhou et al. demonstrate the efficacy and safety of serplulimab plus chemotherapy (nab-paclitaxel and carboplatin) in first-line patients with advanced squamous non-small-cell lung cancer. Compared with placebo plus chemotherapy, serplulimab plus chemotherapy prolongs progression-free survival and overall survival, with a manageable safety profile. Full-Text PDF